The Effects of Therapy With Teriparatide on Vascular Compliance and Osteoprotegerin/RANKL

• Status: Withdrawn
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine what effect teriparatide will have on vascular (blood vessel) compliance and osteoprotegerin (bone fluid)and RANKL levels (bone cells).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Leland Graves III, MD
• Collaborator: University of Kansas
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Postmenopausal women and men over the age of 40 who are starting therapy with teriparatide

Exclusion Criteria:

• Patients with diabetes mellitus

• current smokers

• patients with a history of organ transplantation

• Patients currently of previously on glucocorticoid therapy within the past year

• Patients with serum creatinine above 1.5 mg/dl, patients with uncontrolled hypertension (BP 140/90 or greater)

• Patients ineligible for teriparatide therapy: History of metabolic bone disease other than osteoporosis

• History of radiation therapy

• Patients pregnant or nursing

• History of bone metastasis or skeletal malignancies

• History of hypercalcemia